<DOC>
	<DOCNO>NCT00398333</DOCNO>
	<brief_summary>The purpose study determine nutritional supplement enrich omega-3 fatty acid effective improve tolerance chemotherapy treatment improve quality life .</brief_summary>
	<brief_title>Study Assess Effectiveness Omega-3 Enriched Supplement Chemotherapy Tolerance Colon Cancer Patients</brief_title>
	<detailed_description>Colorectal cancer one main cause mortality western country . It consider case colorectal carcinoma , frequency weight loss moment diagnosis 54 % . Undernourishment affect negatively course illness confers worse prognostic , increase morbidity mortality , entail impairment quality life patient . There narrow relationship oncologic pathology undernourishment pathology , draw common syndrome call cancerous cachexia . It usual patient subject chemotherapy present nutritional alteration due treatment ' side effect . With study want ass efficacy nutritional intervention supplementation enrich EPA improve tolerance antineoplastic treatment . As index tolerability chemotherapy treatment , use variation change quality life evaluate questionnaire EORTC QLQ-C30 , use parameter global quality life physical function .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Patients diagnose metastatic colon adenocarcinoma go receive first line chemotherapy treatment oncology day hospital . Age 18 year old . Patients diagnose colon cancer receive second line chemotherapy . Antecedents malignant tumor exception basocellular epithelioma . Chronic renal failure ( Creatinine &gt; 1.7 ) . Previous diabetes mellitus . Obesity ( IMC &gt; 30 ) Medical condition imply hepatic encephalopathy , ascites . Severe malnutrition accord classification Subjective Global Assessment ( SGA ) BMI &lt; 16.5 . Major psychiatric disorder . Patients receive enteral parenteral nutrition . Contraindications indication nutritional supplement : Galactosemia . Seafood seafood byproduct allergy . Patients take drug affect metabolism ( anabolic steroid , orexigenic agent ... ) . Absence inform consent form sign patient . Any patient disability comply treatment inability accord researcher .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Colorectal Neoplasms</keyword>
	<keyword>Eicosapentaenoic Acid</keyword>
	<keyword>Quality Life</keyword>
	<keyword>Nutritional Status</keyword>
</DOC>